Kelun-Biotech
Latest Rankings
- #19 in 2026 China Innovation View full results
- #8 in 2026 China Invention View full results
In the 2026 China PIII, Kelun-Biotech ranked 19th in Innovation and 8th in Invention. As an innovative biopharmaceutical company focused on oncology, immunology and metabolic diseases, KelunBiotech has built notable R&D strengths in differentiated molecular design and next-generation conjugate development, leveraging its proprietary OptiDC ADC platform and novel conjugation platforms. In 2025, with the approval of multiple innovative products and growing commercial sales, the company progressively transformed from a Biotech into a Biopharma.
The rapid scale-up of sales of its proprietary innovative drugs was Kelun-Biotech's most notable operational change in 2025, giving its revenue structure clearer signs of commercial transformation...
Download the report to see the full company profile.
Download the report
The China Pharmaceutical Innovation and Invention Index, and the accompanying report, explore the performance of individual companies in much greater detail. By accessing our full report, you are given an inside look into our research and findings.
- 1 Methodology and analysis
- 2 Extended profiles of the Top 10 overall companies
- 3 The full top 30 ranking
- 4 The report in full